Phase 1 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form
• People who have a solid tumour that has spread or cannot be surgically removed, confirmed by a tissue or laboratory test, and for which standard treatments have stopped working or could not be tolerated
• For a specific part of the trial (the expansion cohort): people who have pancreatic cancer (adenocarcinoma) that has spread or cannot be surgically removed, confirmed by a tissue or laboratory test, and has not responded to — or could not be tolerated with — all standard treatments, including gemcitabine, nab-paclitaxel, fluoropyrimidine, oxaliplatin, and irinotecan
• People whose cancer can be measured or detected on scans taken within the past 28 days (the expansion cohort requires measurable disease by specific imaging standards)
• People whose heart is functioning adequately, as confirmed by a specific heart scan (the heart must be pumping at more than 50% efficiency)
• People who are reasonably well and able to carry out basic daily activities, based on a standard medical scoring scale (ECOG score of 0, 1, or 2)
• People whose blood test results meet minimum levels for white blood cells, platelets, and haemoglobin, as assessed by the trial site
• People whose liver function blood test results are within acceptable ranges, as assessed by the trial site (slightly higher limits may apply for people with a known liver condition called Gilbert's syndrome or known liver spread)
• People whose kidney function is within acceptable ranges, as assessed by the trial site
• People of reproductive potential who have used highly effective contraception for at least one month before joining and agree to continue using it for three months after the last dose of the study treatment
• People who have signed and dated the consent form
• People who are willing and able to follow all study procedures for the full duration of the trial

Who may not be able to join:

• People who are pregnant or breastfeeding, or people of reproductive potential who are not willing to use effective contraception
• People who still have significant side effects from their most recent cancer treatment that have not returned to their normal baseline or to a mild level (exceptions apply for hair loss and mild nerve-related symptoms)
• People with a history of certain heart or blood vessel conditions, including:
  • A heart attack or unstable chest pain (angina) within the past 6 months
  • Moderate to severe heart failure (classified as New York Heart Association Class II or higher)
  • A stroke or mini-stroke (TIA) within the past 6 months
  • Certain heart rhythm problems, specific electrical conduction abnormalities in the heart, reliance on a pacemaker, or a condition called long QT syndrome
  • A history of a specific inherited heart rhythm condition, or a heart rhythm measurement that is too prolonged (above a certain threshold), or blood mineral levels that cannot be corrected
• People with an active bacterial, fungal, or viral infection confirmed by tests, scans, or symptoms such as fever or septic shock
• People with a known allergy or sensitivity to a group of chemical compounds called 4-aminoquinolines (confirm with trial site)
• People who have changes to their retina or visual field, regardless of the cause
• People with a history of a skin condition called psoriasis
• People with a history of a condition called porphyria (a group of disorders affecting the nervous system or skin)
• People with a known deficiency of an enzyme called G6PD (glucose-6-phosphate dehydrogenase)
• People with a history of seizures
• People with any other condition that the trial site determines could affect their safety or the reliability of the trial results

Important: Always verify eligibility with the trial site directly before applying.